At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 15 enrolled
Drug / intervention
Osimertinib 80 MG [Tagrisso]drug
Likely dose
Osimertinib 80 MG [Tagrisso]from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Osimertinib in NSCLC Patients With EGFR Exon 20 Insertion Mutation
In Brief
A Phase 2 clinical trial evaluating Osimertinib 80 MG [Tagrisso] for Locally Advanced or Metastatic NSCLC. Completed, enrolled 15 participants across 1 site.
Detailed Summary
This is a single-arm, non-randomized multicentre phase 2 study in NSCLC patients with EGFR exon 20 insertion mutation, whose disease has progressed on standard chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLocally Advanced or Metastatic NSCLC
CountriesSouth Korea
CollaboratorsAstraZeneca, Korean Cancer Study Group
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartJan 2018
First PostedJan 2018
Primary CompletionAug 2021
TodayJul 2026
First PostedJan 30, 2018
Enrollment StartJan 4, 2018
Primary CompletionAug 3, 2021
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 8.4 years ago
Interventions
Osimertinib 80 MG [Tagrisso]drug
Osimertinib 80mg once daily until disease progression